@entity1140 , Mycophenolate Mofetil, and Low-Dose XXXX With or  Without Interleukin-2 Receptor Antibody Induction Therapy: A  Retrospective Cohort Analysis.

@entity1 @entity618 @entity1140 @entity230 @entity1011 @entity2902
BACKGROUND: Selective @entity2902 ( @entity2902 ) blockade is one option to decrease acute rejection rates in kidney transplant recipients. However, there are little data on the impact of basiliximab in a triple immunosuppressive regimen ( @entity1140 , @entity618 , and low-dose @entity230 ). Thus, this analysis aims at investigating the impact of basiliximab induction on rejection rates and immediate graft function following kidney transplantation. METHODS: Basiliximab was introduced in our center according to our center's policy in the beginning of 2011. @entity1 who received basiliximab (n  = 83) were compared with @entity1 without induction therapy (n  = 65) transplanted before the introduction of @entity2902 antibody induction. RESULTS: The use of basiliximab as induction therapy decreased the incidence of biopsy-proven acute rejection (BPAR) within the 1st year after transplantation (21.5% vs 14.5%; P  = .283). Overall rejection episodes (including BPAR and borderline rejection) were significantly reduced in @entity1 with basiliximab compared with @entity1 without (41.5% vs 24.1%; P  = .033). However, graft function (incidence of delayed graft function, primary nonfunction, slow graft function, and serum @entity1011 decline) and overall outcome ( @entity1 and graft survivals) were similar in both groups. CONCLUSIONS: We found a favorable impact of basiliximab induction therapy on early acute rejection rate. The impact on long-term outcome must be addressed in further randomized controlled trials.
